INVESTIGATION OF THE EFFECT OF COMPOUND B-47/2 CONTAINING AZOMETHINE GROUP ON ANGIOGENESIS

Abstract

Objective: Lung cancer is one of the most common cancers in the world. It is known that angiogenesis plays a role in the development and metastasis of lung cancer. The anticancer properties of azomethine derivatives known as Schiff bases have been demonstrated. In this study, we aimed to determine the anticancer activity of the newly synthesized azomethine derivative compound B-47/2 on lung cancer and to determine the effect of this component on VEGFB gene expression. Material and Method: Compound B-47/2 was synthesized for the first time. B-47/2 compound was applied to lung cancer cell line A549 at varying concentrations (1-100 µg/mL) and its anticancer activity was found after 24, 48 and 72 incubations using the MTT method. The IC50 dose of B-47/2 was applied to the cells and RNA isolation followed by cDNA synthesis was performed. Then, RT-PCR method was used to determine the expression level of VEGF gene. Results: As a result, it was determined that the B-47/2 compound applied to the A-549 cell line showed the highest cytotoxic activity after 72 hours of incubation. In addition, it was determined that the B-47/2 compound decreased the expression of the VEGFB gene. Discussion: There are studies in which the anticancer activity of azomethine derivatives has been observed. The topic of synthesizing new drugs to prevent cancer is popular. We suggested that the newly synthesized component may have anticancer activity and may be effective on angiogenesis.